Description:
Sonidegib is an orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity. It was approved by the FDA for treating basal-cell carcinoma in July 2015.
- Molecular Weight:485.507
- Purity:>98%
Molecular Formula:
C26H26F3N3O3
Canonical SMILES:
CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F
InChI:
InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+
InChIKey:
VZZJRYRQSPEMTK-CALCHBBNSA-N
Appearance:
Solid Powder
Synonyms:
Erismodegib; LDE225; NVP-LDE225; Odomzo; N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide Weitere Informationen finden Sie
hier